Page last updated: 2024-11-05

thalidomide and Cardiovascular Diseases

thalidomide has been researched along with Cardiovascular Diseases in 14 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis."9.24Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017)
" In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens."9.15Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011)
"Bortezomib has been shown to be highly active in MM patients with RI."5.36Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010)
"Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis."5.24Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017)
" In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens."5.15Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011)
"Pomalidomide entered treatment for the second relapse in 2015 (11% of patients)."1.46Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. ( Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ, 2017)
"Bortezomib has been shown to be highly active in MM patients with RI."1.36Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. ( Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P, 2010)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's7 (50.00)24.3611
2020's6 (42.86)2.80

Authors

AuthorsStudies
Arias de la Rosa, I1
López-Montilla, MD1
Román-Rodríguez, C1
Pérez-Sánchez, C1
Gómez-García, I1
López-Medina, C1
Ladehesa-Pineda, ML1
Ábalos-Aguilera, MDC1
Ruiz, D1
Patiño-Trives, AM1
Luque-Tévar, M1
Añón-Oñate, I1
Pérez-Galán, MJ1
Guzmán-Ruiz, R1
Malagón, MM1
López-Pedrera, C1
Escudero-Contreras, A1
Collantes-Estévez, E1
Barbarroja, N1
Pina Vegas, L3
Claudepierre, P3
Sbidian, E3
Suruki, RY1
Desai, RJ1
Davis, KJ1
Berlin, JA1
Gagne, JJ1
Ouyang, F1
Le Corvoisier, P1
Penso, L1
Paul, M1
Merz, M1
Kellermann, L1
Poenisch, W1
Tischler, HJ1
Kohnke, J1
Knauf, W1
Goldschmidt, H1
Crowley, J1
Thaçi, D1
Joly, P1
Peris, K1
Papp, KA1
Goncalves, J1
Day, RM1
Chen, R1
Shah, K1
Ferrándiz, C1
Cather, JC1
Merlini, G1
Palladini, G1
Li, W1
Garcia, D1
Cornell, RF1
Gailani, D1
Laubach, J1
Maglio, ME1
Richardson, PG1
Moslehi, J1
Fernández Salazar, LI1
Velayos Jiménez, B1
Fernández Galante, I1
Aller de la Fuente, R1
González Hernández, JM1
Morabito, F2
Gentile, M1
Ciolli, S1
Petrucci, MT1
Galimberti, S1
Mele, G1
Casulli, AF1
Mannina, D1
Piro, E1
Pinotti, G1
Palmieri, S1
Catalano, L1
Callea, V2
Offidani, M2
Musto, P1
Bringhen, S2
Baldini, L2
Tosi, P2
Di Raimondo, F1
Boccadoro, M2
Palumbo, A2
Cavo, M2
Prommer, EE1
Twycross, R1
Mihalyo, M1
Wilcock, A1
Zamagni, E1
Romano, A1
Patriarca, F1
Rossi, D1
Gentilini, F1
Crippa, C1
Galli, M1
Nozzoli, C1
Ria, R1
Marasca, R1
Montefusco, V1
Elice, F1
Pulini, S1
Carella, AM1
Zambello, R1
Benevolo, G1
Magarotto, V1
Tacchetti, P1
Pescosta, N1
Cellini, C1
Polloni, C1
Evangelista, A1
Caravita, T1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909]Phase 410 participants (Actual)Interventional2019-09-15Completed
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis[NCT06032858]Phase 430 participants (Actual)Interventional2022-03-06Completed
An Observational Study of Cardiovascular Complications of Carfilzomib Treatment in Clinical Practice[NCT03543579]46 participants (Anticipated)Observational2017-03-23Active, not recruiting
Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978]140 participants (Actual)Observational2022-09-01Completed
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454]Phase 3105 participants (Anticipated)Interventional2014-04-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for thalidomide and Cardiovascular Diseases

ArticleYear
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple

2017
Thalidomide.
    Journal of pain and symptom management, 2011, Volume: 41, Issue:1

    Topics: Abnormalities, Drug-Induced; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, D

2011

Trials

2 trials available for thalidomide and Cardiovascular Diseases

ArticleYear
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal

2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal

2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal

2017
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal

2017
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin

2011

Other Studies

10 other studies available for thalidomide and Cardiovascular Diseases

ArticleYear
The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
    Journal of internal medicine, 2022, Volume: 291, Issue:5

    Topics: Antirheumatic Agents; Arthritis, Psoriatic; Cardiovascular Diseases; Cross-Sectional Studies; Humans

2022
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
    Rheumatology (Oxford, England), 2022, 08-03, Volume: 61, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D

2022
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
    Rheumatology (Oxford, England), 2022, 08-03, Volume: 61, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D

2022
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
    Rheumatology (Oxford, England), 2022, 10-06, Volume: 61, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D

2022
Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
    Rheumatology (Oxford, England), 2022, 10-06, Volume: 61, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Biological Products; Cardiovascular D

2022
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
    Rheumatology (Oxford, England), 2022, 04-11, Volume: 61, Issue:4

    Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Biological Factors; Biological Products; Cardiova

2022
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
    Annals of hematology, 2017, Volume: 96, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiova

2017
Light chain amyloidosis: the heart of the problem.
    Haematologica, 2013, Volume: 98, Issue:10

    Topics: Amyloidosis; Animals; Cardiovascular Diseases; Death; Dexamethasone; Humans; Lenalidomide; Thalidomi

2013
[Efficacy of thalidomide in digestive bleeding caused by angiodysplasias].
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:5

    Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Cardiovascular Diseases; Cerebellar Neoplasms; Cerebe

2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib;

2010